Search results for " Biochemistry"

showing 10 items of 5648 documents

Role of magnesium in insulin action, diabetes and cardio-metabolic syndrome X

2003

Magnesium (Mg) is one of the most abundant ions present in living cells and its plasma concentration is remarkably constant in healthy subjects. Plasma and intracellular Mg concentrations are tightly regulated by several factors. Among them, insulin seems to be one of the most important. In vitro and in vivo studies have demonstrated that insulin may modulate the shift of Mg from extracellular to intracellular space. Intracellular Mg concentration has also been shown to be effective in modulating insulin action (mainly oxidative glucose metabolism), offset calcium-related excitation-contraction coupling, and decrease smooth cell responsiveness to depolarizing stimuli. A poor intracellular M…

medicine.medical_specialtymedicine.medical_treatmentGlucose uptakeClinical BiochemistryBiologyCarbohydrate metabolismBiochemistryInsulin resistanceDiabetes mellitusInternal medicinemedicineHumansInsulinMagnesiumMolecular BiologyMetabolic SyndromeInsulinGeneral Medicinemedicine.diseaseOxidative StressInsulin receptorEndocrinologyDiabetes Mellitus Type 2Hypertensionbiology.proteinMolecular MedicineInsulin ResistanceVanadatesMetabolic syndromeIntracellularMolecular Aspects of Medicine
researchProduct

Improved femoral neck BMD in older Finnish women between 2002 and 2010.

2013

Abstract Purpose The number of hip fractures among Finns over 50-years of age rose constantly between 1970 and 1997, but since then, there has been a nationwide decline in incidence of hip fractures. One possible explanation, although not the only one, for the declining fracture rates, could be improved bone mineral density (BMD). The aim of this study was to evaluate differences in femoral neck BMD between older Finnish women born about a decade apart. Methods We compared the baseline data of two population-based samples of home-dwelling 70–80-year-old women who were initially recruited in exercise intervention studies ( N  = 216 in Cohort1, and N  = 389 in Cohort 2). Femoral neck BMD was …

medicine.medical_specialtymedicine.medical_treatmentOsteoporosisPopulationGeneral Biochemistry Genetics and Molecular BiologyCohort StudiesBone DensitymedicineHumanseducationFinlandOsteoporosis PostmenopausalFemoral neckAgedBone mineralAged 80 and overeducation.field_of_studyAnalysis of Variancebusiness.industryFemur NeckHip FracturesIncidence (epidemiology)IncidenceAge FactorsObstetrics and Gynecologyta3141Baseline datamedicine.diseaseBody Heightmedicine.anatomical_structureCohortPhysical therapyFemaleHormone therapybusinessDemographyMaturitas
researchProduct

Managing Persistent Hypoxemia: what is new?

2017

Mechanical ventilation is the standard life-support technique for patients with severe acute respiratory failure. However, some patients develop persistent and refractory hypoxemia because their lungs are so severely damaged that they are unable to respond to the application of high inspired oxygen concentration and high levels of positive end-expiratory pressure. In this article, we review current knowledge on managing persistent hypoxemia in patients with injured lungs.

medicine.medical_specialtymedicine.medical_treatmentPhysiologyReviewmechanical ventilationGeneral Biochemistry Genetics and Molecular BiologyHypoxemia03 medical and health sciences0302 clinical medicineRefractorysevere acute respiratory failuremedicineAcute respiratory failureIn patientGeneral Pharmacology Toxicology and PharmaceuticsIntensive care medicineMechanical ventilationInspired oxygen concentrationhypoxemiaGeneral Immunology and Microbiologypersistent hypoxemiabusiness.industry030208 emergency & critical care medicineGeneral MedicineArticlesrespiratory tract diseases030228 respiratory systemRespiratory Problems in Critical Caremedicine.symptombusinessF1000Research
researchProduct

Thrombolytic therapy for submassive pulmonary embolism.

2012

Approximately 10% of all patients with acute pulmonary embolism (PE) die within the first three months after diagnosis. However, PE is not universally life-threatening, but covers a wide spectrum of clinical severity and death risk. Thrombolytic treatment is indicated patients with acute massive PE who are at high risk for early death, i.e. those patients who present with arterial hypotension and shock. On the other hand, low molecular-weight heparin or fondaparinux is adequate treatment for most normotensive patients with PE. Recombinant tissue plasminogen activator, given as 100 mg infusion over 2 h, is the treatment of choice for patients with PE, although older regimens using urokinase …

medicine.medical_specialtymedicine.medical_treatmentStreptokinaseVentricular Dysfunction RightClinical Biochemistry030204 cardiovascular system & hematologyFondaparinuxlaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialFibrinolytic AgentslawPolysaccharidesRisk FactorsInternal medicinemedicineHumansStreptokinaseThrombolytic Therapy030212 general & internal medicineIntensive care medicineUrokinaseClinical Trials as Topicbusiness.industryHeparinThrombolysisHeparin Low-Molecular-Weightmedicine.diseaseUrokinase-Type Plasminogen ActivatorTroponin3. Good healthPulmonary embolismRadiographyOncologyFondaparinuxTissue Plasminogen ActivatorAcute DiseaseCardiologybusinessPulmonary EmbolismBiomarkersmedicine.drugCohort studyBest practiceresearch. Clinical haematology
researchProduct

Magnetic Resonance Imaging Derived Biomarkers of IDH Mutation Status and Overall Survival in Grade III Astrocytomas

2020

The evaluation of the isocitrate dehydrogenase (IDH) mutation status in the glioma decision-making process has diagnostic, prognostic and therapeutic implications. The aim of this study was to evaluate whether conventional magnetic resonance imaging (MRI) and apparent diffusion coefficient (ADC) can noninvasively predict the most common IDH mutational status (R132H) in GIII-astrocytomas and the overall survival (OS). Hence, twenty-two patients (9-F, 13-M) with a histological diagnosis of GIII-astrocytoma and evaluation of IDH-mutation status (12-wild type, 10-mutant) were retrospectively evaluated. Imaging studies were reviewed for the morphological feature and mean ADC values (ADCm). Stati…

medicine.medical_specialtyoverall survivalClinical BiochemistryradiogenomicsRadiogenomicsGastroenterologyArticle03 medical and health sciences0302 clinical medicineGliomaInternal medicinemedicineOverall survivalEffective diffusion coefficientdiffusion weighted imaging (DWI)apparent diffusion coefficient (ADC)lcsh:R5-920medicine.diagnostic_testbusiness.industryanaplastic astrocytomaMagnetic resonance imagingmedicine.diseaseExact testIsocitrate dehydrogenaseisocitrate dehydrogenase (IDH) mutation030220 oncology & carcinogenesisHuman medicinelcsh:Medicine (General)businessanaplastic astrocytomas030217 neurology & neurosurgeryAnaplastic astrocytomaDiagnostics
researchProduct

Immunologic microenvironment and personalized treatment in multiple myeloma.

2013

Introduction: Multiple myeloma (MM) is characterized by generalized immune suppression and increased susceptibility to infections and secondary malignancies. Malignant plasma cells (PCs) modulate the bone marrow microenvironment to favor their own survival and proliferation. These events lead to a severe deregulation of immune effectors. Extensive studies have been conducted to unveil the mechanisms through which MM cells negatively modulate immunity and to develop therapeutical approaches for restoring an efficient anti-MM immune response. Areas covered: This review article covers both the immunosuppressive effects exerted by MM and the immunomodulatory potential of novel anti-MM agents. A…

medicine.medical_treatmentClinical BiochemistryAntineoplastic AgentsImmune systemImmunityDrug DiscoveryTumor MicroenvironmentMedicineHumansPrecision MedicineMultiple myelomaBone marrow microenvironmentPharmacologyTumor microenvironmentbusiness.industryImmunotherapymedicine.diseaseReview articlemedicine.anatomical_structurePersonalized treatmentImmune SystemImmunologyBone marrowPersonalized medicineImmunotherapybusinessMultiple MyelomaExpert opinion on biological therapy
researchProduct

Stability of Cannabinoids in Hair Samples Exposed to Sunlight

2000

It has been well recognized that hashish and marihuana lose potency during storage because of a decrease in the content of tetrahydrocannabinol (THC), which is the major psychoactive constituent of cannabis (1). The effect of oxygen on stored plant and resin materials or solutions of pure cannabinoids seems much less significant than that of higher temperatures (≥37 °C) or light (2)(3)(4)(5)(6)(7). A few data are available on the stability of THC and major metabolites in blood (8)(9)(10)(11). However, the stability of cannabinoids in the hair shaft has not been addressed, although scalp hair represents one of the most exposed parts of the body. Therefore, a study was performed to elucidate …

medicine.medical_treatmentClinical BiochemistryCannabinolAnalytical chemistryHashishSpecimen HandlingMatrix (chemical analysis)chemistry.chemical_compoundmedicineCannabidiolHumansDronabinolTetrahydrocannabinolDichloromethaneChromatographybiologyCannabinoidsBiochemistry (medical)biology.organism_classificationSubstance Abuse DetectionchemistrySunlightCannabinolCannabinoidCannabisCannabidiolHairmedicine.drugClinical Chemistry
researchProduct

Monoclonal antibodies for the treatment of non-haematological tumours: update of an expanding scenario.

2015

Abstract: Introduction: The identification of cell membrane-bound molecules with a relevant role in cancer cell survival prompted the development of moAbs to block the related pathways. In the last few years, the number of approved moAbs for cancer treatment has constantly increased. Many of these drugs significantly improved the survival outcomes in patients with solid tumours. Areas covered: In this review, all the FDA-approved moAbs in solid tumours have been described. This is an update of moAbs available for cancer treatment nowadays in comparison with the moAbs approved until few years ago. The moAbs under development are also discussed here. Expert opinion: The research on cancer ant…

medicine.medical_treatmentClinical BiochemistryCellReceptor activator of nuclear factor κB ligandCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)NeoplasmsMonoclonalDrug DiscoveryDrug approvalCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all); Cancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies; Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)Drug ApprovalCancerbiologyMedicine (all)Antibodies MonoclonalVEGFReceptor activator of nuclear factor κB ligandmedicine.anatomical_structureMonoclonalMoAbsImmunotherapyAntibodyEngineering sciences. TechnologyHumanUnited StateCancer; Cancer antigen; Cytotoxic T-lymphocyte antigen 4; EGFR; HER2; Immunotherapy; MoAbs; Receptor activator of nuclear factor κB ligand; VEGF; Antibodies Monoclonal; Drug Approval; Drug Discovery; Humans; Immunotherapy; Neoplasms; United States; United States Food and Drug Administration; Pharmacology; Clinical Biochemistry; Drug Discovery3003 Pharmaceutical Science; Medicine (all)medicine.drug_classEGFRMonoclonal antibodyAntibodiesCancer antigenCytotoxic T-lymphocyte antigen 4HER2medicineHumansBiologyPharmacologybusiness.industryUnited States Food and Drug AdministrationDrug Discovery3003 Pharmaceutical ScienceCancerImmunotherapymedicine.diseaseUnited StatesImmunologyCancer cellCancer researchbiology.proteinNeoplasmMoAbHuman medicinebusinessExpert opinion on biological therapy
researchProduct

Enantioselective determination of plasma protein binding of common amphetamine-type stimulants.

2021

Amphetamine-type stimulants (ATS) like amphetamine ('speed'), methamphetamine ('crystal meth') and 3,4-methylenedioxy-N-methylamphetamine (MDMA, 'ecstasy') represent some of the most frequently abused drugs worldwide. Another less frequently abused ATS is 4-fluoroamphetamine (4-FA). The enantiomers of these four compounds exhibit different pharmacokinetic and pharmacodynamic properties. According to the free drug theory, the pharmacological properties of a substance are dependent on its plasma protein binding (PPB). However, data on PPB of stimulant enantiomers in humans are rare or non-existent. Human plasma samples were spiked with racemic mixtures of the stimulants and subjected to ultra…

medicine.medical_treatmentClinical BiochemistryPharmaceutical ScienceTandem mass spectrometryAnalytical ChemistryPharmacokineticsTandem Mass SpectrometryDrug DiscoverymedicineHumansAmphetamineSpectroscopyChromatographyChemistryIllicit DrugsForensic toxicologyMDMAStereoisomerismMethamphetamineStimulantAmphetamineCentral Nervous System StimulantsEnantiomermedicine.drugChromatography LiquidProtein BindingJournal of pharmaceutical and biomedical analysis
researchProduct

Optimized culture conditions for tissue explants of uterine leiomyoma

2012

Background Uterine leiomyomas are the most common benign tumours in women, which arise from smooth muscle cells of the uterine myometrium and usually are multicentric. In spite of their frequency pathogenesis is widely unknown, mainly due to the absence of a suitable model system. We describe the systematic optimization of culturing leiomyoma tissue explants in an economical and effective ex vivo system. Methods Different concentrations of oxygen, different media, sera, hormones, and growth factor supplements were tested. Immunohistochemical stainings with antibodies against hormone receptors as well as specifying proliferation and apoptotic indices and real-time PCR were performed. Results…

medicine.medical_treatmentCulture Media; Epidermal Growth Factor; Estradiol; Female; Humans; Immunohistochemistry; Leiomyoma; Progesterone; RNA Messenger; Real-Time Polymerase Chain Reaction; Uterine NeoplasmsBiologyReal-Time Polymerase Chain ReactionGeneral Biochemistry Genetics and Molecular BiologyAndrologyTissue culturemedicineHumansRNA MessengerUterine NeoplasmProgesteroneUterine leiomyomaEpidermal Growth FactorEstradiolLeiomyomaGrowth factorMyometriummedicine.diseaseImmunohistochemistrySettore MED/40 - Ginecologia E OstetriciaCulture MediaLeiomyomaHormone receptorUterine NeoplasmsFemaleEx vivoHuman
researchProduct